دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis
Francisco Tsz Tsun Lai, PHD, a,b, * Edward Wai Wa Chan, MPH,a,b, * Lei Huang, MS C,a,b Ching Lung Cheung, PHD, a,b Celine Sze Ling Chui, PHD, b,c,d Xue Li, PHD, b,e Eric Yuk Fai Wan, P HD, a,b,f Carlos King Ho Wong, P HD, a,b,f Esther Wai Yin Chan, PH D, a,b Kai Hang Yiu, MD, PHD, g,h Ian Chi Kei Wong, PHD
doi : 10.1016/j.jacc.2022.09.049
Volume 80, Issue 24, 13 December 2022, Pages 2255-2265
Association between messenger RNA (mRNA) COVID-19 vaccines and myocarditis has aroused public concern over vaccine safety.
COVID-19 Vaccine Myocarditis∗: Cautious Reassurance in an Era of Dynamic Uncertainty
Peter P. Liu, MD, Tahir S. Kafil, MD
doi : 10.1016/j.jacc.2022.10.010
Volume 80, Issue 24, 13 December 2022, Pages 2266-2268
Micronutrient Supplementation to Reduce Cardiovascular Risk
Peng An, PHD, a, * Sitong Wan, BS C,a, * Yongting Luo, PH D, a Junjie Luo, P HD, a Xu Zhang, MS C,a Shuaishuai Zhou, MS C,a Teng Xu, MSC ,a Jingjing He, PH D, a Jeffrey I. Mechanick, MD, b Wen-Chih Wu, MD, MPH,c,d,e Fazheng Ren, PHD, a Simin Liu, MD, SC D
doi : 10.1016/j.jacc.2022.09.048
Volume 80, Issue 24, 13 December 2022, Pages 2269-2285
Healthy dietary patterns are rich in micronutrients, but their influence on cardiovascular disease (CVD) risks has not been systematically quantified.
Antioxidant Supplementation in Cardiovascular Prevention∗: New Challenges in the Face of New Evidence
Juan G. Gormaz, PH D, a Rodrigo Carrasco, MD, P HD
doi : 10.1016/j.jacc.2022.10.011
Volume 80, Issue 24, 13 December 2022, Pages 2286-2288
Incidence and Burden of Tricuspid Regurgitation in Patients With Atrial Fibrillation
Sri Harsha Patlolla, MBBS, MS, a,b Hartzell V. Schaff, MD, a Rick A. Nishimura, MD, c John M. Stulak, MD, a Alanna M. Chamberlain, PHD, MPH, c,d Sorin V. Pislaru, MD, P HD, c Vuyisile T. Nkomo, MD, MPH c
doi : 10.1016/j.jacc.2022.09.045
Volume 80, Issue 24, 13 December 2022, Pages 2289-2298
Atrial fibrillation (AF) is considered a risk factor for isolated tricuspid valve regurgitation (TR) in the absence of other known etiologies.
Understanding Atrial Fibrillation and Atrial Secondary Tricuspid Regurgitation: The Chicken or the Egg?∗
Tobias Friedrich Ruf, MD, Theresa Ann Maria Gößler, MD, Ralph Stephan von Bardeleben, MD
doi : 10.1016/j.jacc.2022.10.009
Volume 80, Issue 24, 13 December 2022, Pages 2299-2300
Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease
Michael A. Portman, MD, a, * Jeffrey P. Jacobs, MD, b, * Jane W. Newburger, MD, MPH,c Felix Berger, MD,d Michael A. Grosso, MD,e Anil Duggal, MD, e Ben Tao, MS,e Neil A. Goldenberg, MD, P HD, f,g on behalf of the ENNOBLE-ATE Trial Investigators
doi : 10.1016/j.jacc.2022.09.031
Volume 80, Issue 24, 13 December 2022, Pages 2301-2310
Standard of care (SOC) anticoagulation for thromboembolism (TE) prevention in children with cardiac disease includes low molecular weight heparins or vitamin K antagonists. Limited data exists for alternate use of direct oral anticoagulants in children.
Advancing Anticoagulation for Children With Cardiac Disease∗
Nadine F. Choueiter, MD
doi : 10.1016/j.jacc.2022.10.006
Volume 80, Issue 24, 13 December 2022, Pages 2311-2313
Pathophysiology, Echocardiographic Diagnosis, and Treatment of Atrial Functional Mitral Regurgitation: JACC State-of-the-Art Review
Serdar Farhan, MD, a, * Jeffrey J. Silbiger, MD,a,b, * Jonathan L. Halperin, MD, a Lily Zhang, MD, a Srinivas R. Dukkipati, MD,a Birgit Vogel, MD, a Annapoorna Kini, MD,a Samin Sharma, MD, a Stamatios Lerakis, MD, PHD
doi : 10.1016/j.jacc.2022.09.046
Volume 80, Issue 24, 13 December 2022, Pages 2314-2330
The conventional view holds that functional mitral regurgitation (MR) is caused by restriction of leaflet motion resulting from displacement of the papillary muscle-bearing segments of the left ventricle.
Research Opportunities in the Treatment of Mitral Valve Prolapse: JACC Expert Panel
Francesca N. Delling, MD, MPH,a Peter A. Noseworthy, MD, b David H. Adams, MD,c Cristina Basso, MD,d Michael Borger, MD, e Nabila Bouatia-Naji, PHD, f Sammy Elmariah, MD,a,g Frank Evans, PH D, h Edward Gerstenfeld, MD,a Judy Hung, MD, g Thierry Le Tourneau, MD,i John Lewis,j Marc A. Miller, MD, k Russell A. Norris, PHD, l Muralidhar Padala, PHD, m Martina Perazzolo-Marra, MD,n Dipan J. Shah, MD, o Jonathan W. Weinsaft, MD, p Maurice Enriquez-Sarano, MD,q Robert A. Levine, MD
doi : 10.1016/j.jacc.2022.09.044
Volume 80, Issue 24, 13 December 2022, Pages 2331-2347
In light of the adverse prognosis related to severe mitral regurgitation, heart failure, or sudden cardiac death in a subset of patients with mitral valve prolapse (MVP), identifying those at higher risk is key.
2022 Aortic Disease Guideline-at-a-Glance
doi : 10.1016/j.jacc.2022.10.001
Volume 80, Issue 24, 13 December 2022, Pages 2348-2352
ACC/AHA Aortic Disease Guidelines: What Was Simple Is Now Complex—Moving to Multidisciplinary Teams, Specialized Centers
Marc P. Bonaca, MD, MPH,a Jeffrey W. Olin, DO
doi : 10.1016/j.jacc.2022.11.007
Volume 80, Issue 24, 13 December 2022, Pages 2353-2355
2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
doi : 10.1016/j.jacc.2022.08.004
Volume 80, Issue 24, 13 December 2022, Pages e223-e393
The “2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease� provides recommendations to guide clinicians in the diagnosis, genetic evaluation and family screening, medical therapy, endovascular and surgical treatment, and long-term surveillance of patients with aortic disease across its multiple clinical presentation subsets (ie, asymptomatic, stable symptomatic, and acute aortic syndromes).
Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab
Gregory G. Schwartz, MD, PhD Michael Szarek, PhD Andreas Zeiher, MD Harvey D. White, DSc J. Wouter Jukema, MD, PhD Robert A. Harrington, MD Shaun G. Goodman, MD Rafael Diaz, MD Vera Bittner, MD, MPH Deepak L. Bhatt, MD, MPH Ph. Gabriel Steg, MD
doi : 10.1016/j.jacc.2022.09.035
Volume 80, Issue 24, 13 December 2022, Pages 2356-2359
The Relationship Between Cardiorespiratory Fitness and Mortality
Aihong Pan, MS Chenyu Sun, MD, MSc Scott Lowe, BS Vicky Yau, DDS *Yuyan Wu, MSN, RN
doi : 10.1016/j.jacc.2022.08.811
Volume 80, Issue 24, 13 December 2022, Page e395
Reply: The Relationship Between Cardiorespiratory Fitness and Mortality
Peter Kokkinos, PhD Charles Faselis, MD Jonathan Myers, PhD
doi : 10.1016/j.jacc.2022.09.047
Volume 80, Issue 24, 13 December 2022, Page e397
